2.
各ICIs所致ir-AEs的总体发病率
The overall incidence of ir-AEs induced by ICIs
| ICIs | All-grade ir-AEs incidence (%) (95%CI) |
High-grade ir-AEs incidence (%) (95%CI) |
| ir-AEs: immune-related adverse events; ICIs: immune checkpoint inhibitors. | ||
| PD-1 | 4.3 (2.6-7.0) | 0.6 (0.3-1.1) |
| PD-L1 | 1.9 (0.7-4.9) | 0.7 (0.5-0.9) |
| CTLA-4 | 5.2 (2.0-13.4) | 2.1 (1.0-4.7) |
| PD-1+CTLA-4 | 12.2 (7.6-19.6) | 4.9 (3.3-7.2) |
| Overall | 5.1 (2.4-10.9) | 1.4 (0.5-4.4) |